|  |  |
| --- | --- |
|  | |
| Journal Name: | [**Journal of Cancer and Tumor International**](https://journaljcti.com/index.php/JCTI) |
| Manuscript Number: | **Ms\_JCTI\_144316** |
| Title of the Manuscript: | **Integrative Bioinformatics Analysis of microRNA Expression and Genomic Signatures for Early Detection and Survival Prediction in Prostate Cancer** |
| Type of the Article |  |

|  |  |  |
| --- | --- | --- |
| PART 1: Comments | | |
|  | Reviewer’s comment **Artificial Intelligence (AI) generated or assisted review comments are strictly prohibited during peer review.** | **Author’s Feedback** (It is mandatory that authors should write his/her feedback here) |
| **Please write a few sentences regarding the importance of this manuscript for the scientific community. A minimum of 3-4 sentences may be required for this part.** | The manuscript presents a comprehensive integrative bioinformatics analysis of microRNA (miRNA) expression and genomic signatures in prostate cancer using TCGA and GEO datasets. The work is timely, relevant, and addresses an important gap in prostate cancer biomarker discovery. The methodology is detailed, results are robust, and the discussion provides strong clinical implications. However, certain areas require refinement for clarity, rigor, and improved presentation. |  |
| **Is the title of the article suitable?**  **(If not please suggest an alternative title)** | The current title “Integrative Bioinformatics Analysis of microRNA Expression and Genomic Signatures for Early Detection and Survival Prediction in Prostate Cancer” is informative and reflects the scope of the study. However, it is somewhat long and could be made more concise to improve clarity and impact.  Suggested alternative titles:   1. “Integrative Analysis of microRNA and Genomic Signatures for Early Detection and Prognosis in Prostate Cancer” 2. “Bioinformatics-Based miRNA and Genomic Signatures for Prostate Cancer Diagnosis and Survival Prediction” 3. “microRNA and Genomic Signature Profiling for Early Detection and Prognostic Stratification in Prostate Cancer” |  |
| Is the abstract of the article comprehensive? Do you suggest the addition (or deletion) of some points in this section? Please write your suggestions here. | The abstract is comprehensive, but it is currently too detailed and lengthy, which may reduce its clarity and impact. I recommend condensing the methodological descriptions and highlighting only the most significant findings, such as the key dysregulated miRNAs and the performance metrics of the diagnostic and prognostic signatures. The conclusion should emphasize the clinical applicability of these signatures for early detection and personalized management of prostate cancer. Overall, the abstract should remain within 250–300 words and present the study in a more concise, reader-friendly manner. |  |
| Is the manuscript scientifically, correct? Please write here. | Yes, the manuscript is scientifically correct. The methodology is rigorous and the analyses are appropriate, though some parameters (e.g., cutoff thresholds) need clearer justification and prognostic tables should include hazard ratios and confidence intervals. Minor refinements in presentation are recommended. |  |
| **Are the references sufficient and recent? If you have suggestions of additional references, please mention them in the review form.** | Yes, the references are sufficient and mostly recent. However, some older citations could be updated, and recent works on circulating miRNAs and integrative multi-omics (e.g., Front Oncol. 2021;11:736290 and Nat Commun. 2021;12:6644) are recommended to strengthen the clinical and translational context. |  |
| Is the language/English quality of the article suitable for scholarly communications? | Yes, the English is clear and suitable for scholarly communication, though minor grammatical corrections and consistency in terminology are recommended. |  |
| Optional/General comments | A strong and relevant study; revisions should focus on conciseness, clarity, and translational emphasis to maximize impact.  The study is scientifically sound, original, and relevant.  The methodology is rigorous and validated with independent cohorts.  However, the manuscript is currently too detailed in places, with methodological descriptions overlapping the Results and Discussion sections. Figures are sometimes repetitive, and prognostic tables would be stronger with hazard ratios and confidence intervals included. The abstract should be condensed, and the discussion streamlined to reduce redundancy while emphasizing translational and clinical implementation aspects, including cost-effectiveness and feasibility of liquid biopsy approaches.  With revisions aimed at improving clarity, conciseness, and focus on clinical applicability, the manuscript will represent a valuable contribution to prostate cancer biomarker research and precision medicine. |  |

|  |  |  |
| --- | --- | --- |
| **PART 2:** | | |
|  | Reviewer’s comment | **Author’s Feedback** (It is mandatory that authors should write his/her feedback here) |
| **Are there ethical issues in this manuscript?** | *(No ethical issues are identified; the study relies on publicly available datasets (TCGA, GEO) with appropriate use.* |  |

**Reviewer details:**

**Enaam Junainah , Saudi Arabia**